证券代码:300452 证券简称:山河药辅 公告编号：2025-045 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于选举产生第六届董事会职工代表董事的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特此公告。 安徽山河药用辅料股份有限公司 董事会 2025 年 8 月 18 日 附件：王传珍先生简历 王传珍先生：1988 年 3 月生，中国国籍，无境外永久居留权。 本科毕业于中国药科大学药学专业，获取理学学士学位，执业药师（药 学、中药学），2007 年加入公司；2007 年至今，历任公司销售经理、 大客户经理、大区经理职位；2024 年 5 月至 2025 年 8 月，任公司监 事；现任公司市场部经理。 王传珍先生持有公司股份 12,700 股。与公司控股股东、实际控 制人、持有公司 5%以上股份的股东以及其他董事和高级管理人员不 存在关联关系。王传珍先生未受过中国证监会及其他有关部门的处罚 或交易所的惩戒，不存在《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》第 3.2.3 条、3.2.4 条所规定的 情 ...

Core Points - The company, Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd., has issued convertible bonds to unspecified investors, with a total fundraising amount of RMB 320 million [3][4] - The bonds have a maturity period of 6 years, from June 12, 2023, to June 11, 2029, with a tiered interest rate structure [4][5] - The company has signed an investment agreement with the Huainan Economic and Technological Development Zone Management Committee to establish a high-end auxiliary material manufacturing base, with a total investment of RMB 1.05 billion [7][8] Group 1: Bond Issuance Details - The bond issuance was approved by the company's board on July 12, 2022, and by the shareholders on August 2, 2022 [3] - The bonds are issued at a face value of RMB 100 each, with a total of 3.2 million bonds issued [4] - The net proceeds from the bond issuance, after deducting issuance costs, amount to RMB 316.07 million [4] Group 2: Bond Terms and Conditions - The interest rates for the bonds are structured as follows: 0.2% for the first year, 0.5% for the second year, 1.0% for the third year, 1.5% for the fourth year, 2.0% for the fifth year, and 3.0% for the sixth year [4][5] - The bonds will pay interest annually, with the first interest payment occurring one year after the issuance date [5][6] - The initial conversion price for the bonds is set at RMB 18.25 per share, with the current conversion price at RMB 13.30 per share [6][7] Group 3: Project Investment Agreement - The investment project covers approximately 200 acres, with a total investment of RMB 1.05 billion, including RMB 600 million for fixed assets [8][9] - The project will be constructed in two phases, with the first phase covering 100 acres and an investment of RMB 450 million [8] - The project aims to establish intelligent production lines and quality inspection facilities for high-end auxiliary materials [8][9] Group 4: Regulatory and Compliance Aspects - The investment agreement requires the company to obtain necessary approvals, including environmental assessments and construction permits [11] - The agreement does not constitute a related party transaction or a major asset restructuring as per regulatory definitions [11] - The company is committed to complying with all relevant laws and regulations during the project execution [10][11]

证券代码：300452 证券简称：山河药辅 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 向不特定对象发行可转换公司债券 第一次临时受托管理事务报告 （2025 年度） 债券受托管理人 （安徽省合肥市梅山路 18 号） 二〇二五年八月 根据 《管理办法》 《行为准则》《可转换公司债券管理办法》等相关规定、本 次债券《受托管理协议》的约定以及发行人披露的《关于公司与淮南经济技术开 发区管理委员会签订项目投资协议书的公告》（公告编号：2025-041），现就本次 债券重大事项报告如下： 一、注册文件及注册规模 本次向不特定对象发行可转换公司债券发行方案经山河药辅 2022 年 7 月 12 日召开的第五届董事会第七次会议审议通过，于 2022 年 8 月 2 日经公司 2022 年 度第一次临时股东大会审议通过。2022 年 8 月 8 日，公司召开第五届董事会第 八次会议对本次发行方案予以更新。 经中国证券监督管理委员会《关于同意安徽山河药用辅料股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕268 号）同意注 册，公司于 2023 年 6 月向不特定对 ...

Core Viewpoint - The announcement by the company regarding the addition of a new pharmaceutical excipient product, Mannitol Core, is expected to positively impact the company's operations in the coming years [2]. Group 1: Product Details - The newly added product, Mannitol Core, has received the registration number F20250000241 from the National Medical Products Administration [1]. - As of the announcement date, the company has a total of 47 products with CDE registration numbers [1]. - Mannitol Core is a white or off-white spherical pellet made from D-mannitol and other excipients, primarily used as a carrier for enteric-coated micro-pellets and controlled-release micro-pellets [1]. Group 2: Product Features - Mannitol Core serves as an ideal platform for drug layering due to its smooth surface and uniform particle size distribution, ensuring even and secure drug layering [1]. - It acts as an inert core for preparing controlled-release micro-pellets, allowing the release characteristics to be primarily controlled by the coating membrane [1]. - The product improves taste, as mannitol has a cooling sweetness and produces a cooling sensation upon dissolution [1]. - It enables the preparation of compound formulations, allowing different drugs to be loaded onto separate batches of Mannitol Core, thus avoiding incompatibility between different drug components and achieving varied release rates [1]. - Mannitol Core can also be used directly as an osmotic diuretic [1].

山河药辅（300452）(300452.SZ)公告，公司新增1种药用辅料产品：甘露醇丸芯获得国家药品监督管理 局药品审评中心(简称"CDE")的登记号，为F20250000241。甘露醇丸芯是由D-甘露糖醇及其他辅料制成 的白色或类白色球形小丸，主要用作肠溶微丸制剂和缓控释微丸制剂的载体，也可直接作为药物微丸。 ...

Core Viewpoint - Shanhe Pharmaceutical Excipients Co., Ltd. has recently received a registration number for a new pharmaceutical excipient product, Mannitol Pill Core, from the National Medical Products Administration (NMPA) [1] Company Summary - Shanhe Pharmaceutical Excipients has a total of 47 products that have received registration numbers from the NMPA as of the announcement date [1] - The newly registered Mannitol Pill Core is made from D-mannitol and other excipients, and is primarily used as a carrier for enteric-coated micro-pellets and sustained-release micro-pellets, and can also be used directly as a drug micro-pellet [1]

Core Viewpoint - The company Shanhe Pharmaceutical Auxiliary (300452.SZ) has announced the registration of a new pharmaceutical excipient product, Mannitol Core, with the National Medical Products Administration (NMPA) [1] Group 1 - The newly registered product, Mannitol Core, has the registration number F20250000241 [1] - Mannitol Core is composed of D-mannitol and other excipients, characterized as white or off-white spherical granules [1] - The primary applications of Mannitol Core include serving as a carrier for enteric-coated microgranules and sustained-release microgranules, and it can also be used directly as a drug microgranule [1]

证券代码:300452 证券简称:山河药辅 公告编号：2025-043 债券代码:123199 债券简称:山河转债 公司新增产品品种，扩大了公司产品生产范围,将对公司后续年 度的经营产生一定的积极影响。同时敬请广大投资者谨慎投资，注意 防范投资风险。 特此公告。 安徽山河药用辅料股份有限公司 关于公司新增产品品种的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 近日安徽山河药用辅料股份有限公司（以下简称"山河药辅"或 "公司"）新增 1 种药用辅料产品：甘露醇丸芯获得国家药品监督管 理局药品审评中心（以下简称"CDE"）的登记号，为 F20250000241。 截止公告日，山河药辅已有 47 种产品获得 CDE 登记号，详情登陆 CD E 官网（http://www.cde.org.cn/）查询。 根据国家药品监督管理局发布公告称，为贯彻落实中共中央办公 厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创 新的意见》（厅字〔2017〕42 号）与《国务院关于取消一批行政许 可事项的决定》（国发〔2017〕46 号），各级食品药品监督管理部 门不再单独受理原料 ...

每经AI快讯，山河药辅（SZ 300452，最新价：14元）7月31日晚间发布公告称，公司第六届第六次董事 会会议于2025年7月31日在公司三楼会议室召开。会议审议了《关于修订 <董事会议事规则> 的议案》 等文件。 2024年1至12月份，山河药辅的营业收入构成为：医药制造业占比100.0%。 每经头条（nbdtoutiao）——"我们也深陷残酷价格战"！德资巨头中国区高管警告：智驾绝不能免费， 否则会给全行业带来灾难 （记者 王瀚黎） ...

Group 1 - The core viewpoint of the news is that Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. has shown a slight increase in revenue but a decrease in net profit in its latest quarterly report [1] - As of August 1, 2025, the company's stock price closed at 14.31 yuan, down 2.32%, with a trading volume of 239,600 hands and a transaction amount of 353 million yuan [1] - The company's main funds experienced a net outflow of 13.46 million yuan, accounting for 3.82% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 248 million yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders decreased by 5.30% to 47.18 million yuan [1] - The company has a current ratio of 4.936, a quick ratio of 4.556, and a debt-to-asset ratio of 35.72% [1] - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 2.34 billion yuan [1][2]